MEDIA

Nanexa granted patent in South Korea

22 June, 2021
- Press Release
Download attachment

Nanexa AB (publ) today announced that the company has been granted a patent in South Korea relating to PharmaShell®-coated drugs.

"Our primary patent has now been granted in the important markets of the USA, Japan, China and South Korea. We continue to strengthen our broad patent protection which is very encouraging,” said David Westberg, CEO of Nanexa.

The patent application for the primary patent for the drug delivery system has also been filed in the European Patent Office, Canada and India.
 

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with several pharma companies, among others AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Nanexa granted patent in South Korea